GLOBE NEWSWIRE, December 26, 2024 – An inquiry into possible violations of the federal securities laws has been announced by leading securities law firm Bleichmar Fonti & Auld LLP into BioAge Labs Faces Legal Labs, Inc. BIOA.
BioAge Labs’ Azelaprag for Obesity Treatment
BioAge Labs, Inc., a clinical-stage biopharmaceutical business, focuses on therapeutic product development for metabolic illnesses, particularly obesity. The company’s prime candidate, Azelaprag, is a small-molecule agonist of the apelin receptor (APJ) that can be taken orally and is intended to promote weight loss.
According to the company’s statements during that time, azelaprag was well-tolerated in 265 individuals across 8 Phase 1 clinical trials, and the business was “well-equipped to advance our clinical programs” after its initial public offering.
BioAge Halts Azelaprag Trial Due to Safety Issues
BioAge Labs Faces Legal said on December 6, 2024, that it had stopped the STRIDES Phase 2 trial because of safety concerns after people who were given azelaprag got liver transaminitis. According to the company, the decision to end the STRIDES Phase 2 research of azelaprag “became clear. Because of “the emerging safety profile of the current doses tested. After reaching a high of $20.09 per share on December 6, 2024. The corporation’s stock price plummeted to $4.65 per share on December 9, 2024, due to this news.
BioAge Investors May Have Legal Options
If you invested in BioAge you may have BioAge Labs Faces Legal are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Bleichmar Fonti Auld LLP Top Securities Litigators
For shareholder and securities class action litigation, go no further than Bleichmar Fonti Auld LLP, a leading worldwide law company. Its lawyers have been recognized as SuperLawyers by Thompson Reuters and Titans of the Plaintiffs’ Bar by Law360. The firm was ranked among the top five plaintiff law firms in 2023 by ISS SCAS. Recovering nearly $900 million in value from Tesla. Inc.’s Board of Directors (pending court approval) and $420 million from Teva Pharmaceutical Ind. Ltd. are among BFA’s recent notable wins.
[sp_easyaccordion id=”3453″]
